vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $21.9M, roughly 1.2× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -49.7%, a 56.9% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 13.1%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 1.8%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
BCBP vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $21.9M |
| Net Profit | $-12.0M | $1.6M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | 9.0% |
| Net Margin | -49.7% | 7.2% |
| Revenue YoY | 13.1% | 1292.3% |
| Net Profit YoY | -467.6% | 116.7% |
| EPS (diluted) | $-0.73 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $21.9M | ||
| Q3 25 | $26.5M | $2.1M | ||
| Q2 25 | $25.2M | $3.0M | ||
| Q1 25 | $23.8M | $421.0K | ||
| Q4 24 | $23.1M | $1.6M | ||
| Q3 24 | $26.2M | $3.3M | ||
| Q2 24 | $20.4M | $2.7M | ||
| Q1 24 | $25.3M | $1.7M |
| Q4 25 | $-12.0M | $1.6M | ||
| Q3 25 | $4.3M | $-7.4M | ||
| Q2 25 | $3.6M | $-8.5M | ||
| Q1 25 | $-8.3M | $-12.3M | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $6.7M | $-8.7M | ||
| Q2 24 | $2.8M | $-10.2M | ||
| Q1 24 | $5.9M | $-12.3M |
| Q4 25 | -71.9% | 9.0% | ||
| Q3 25 | 21.9% | -353.4% | ||
| Q2 25 | 19.9% | -292.3% | ||
| Q1 25 | -49.2% | -2921.4% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 35.7% | -264.2% | ||
| Q2 24 | 19.5% | -390.6% | ||
| Q1 24 | 33.0% | -737.8% |
| Q4 25 | -49.7% | 7.2% | ||
| Q3 25 | 16.1% | -346.6% | ||
| Q2 25 | 14.2% | -287.1% | ||
| Q1 25 | -35.0% | -2911.4% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 25.5% | -259.6% | ||
| Q2 24 | 13.8% | -382.7% | ||
| Q1 24 | 23.2% | -719.1% |
| Q4 25 | $-0.73 | $0.05 | ||
| Q3 25 | $0.22 | $-0.07 | ||
| Q2 25 | $0.18 | $-0.09 | ||
| Q1 25 | $-0.51 | $-0.17 | ||
| Q4 24 | $0.17 | — | ||
| Q3 24 | $0.36 | $-0.17 | ||
| Q2 24 | $0.14 | $-0.20 | ||
| Q1 24 | $0.32 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $26.4M |
| Total Assets | $3.3B | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $11.7M | ||
| Q2 25 | — | $27.5M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $22.5M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | — | $30.0M | ||
| Q1 24 | — | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $304.3M | $26.4M | ||
| Q3 25 | $318.5M | $13.2M | ||
| Q2 25 | $315.7M | $18.2M | ||
| Q1 25 | $314.7M | $6.6M | ||
| Q4 24 | $323.9M | $17.5M | ||
| Q3 24 | $328.1M | $25.4M | ||
| Q2 24 | $320.7M | $21.6M | ||
| Q1 24 | $320.1M | $30.0M |
| Q4 25 | $3.3B | $42.2M | ||
| Q3 25 | $3.4B | $31.6M | ||
| Q2 25 | $3.4B | $40.7M | ||
| Q1 25 | $3.5B | $22.3M | ||
| Q4 24 | $3.6B | $32.2M | ||
| Q3 24 | $3.6B | $44.8M | ||
| Q2 24 | $3.8B | $42.3M | ||
| Q1 24 | $3.8B | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-1.1M |
| Free Cash FlowOCF − Capex | $34.9M | — |
| FCF MarginFCF / Revenue | 133.3% | — |
| Capex IntensityCapex / Revenue | 4.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-1.1M | ||
| Q3 25 | $8.7M | $-9.0M | ||
| Q2 25 | $10.3M | $-3.4M | ||
| Q1 25 | $5.0M | $-8.2M | ||
| Q4 24 | $67.7M | $-36.3M | ||
| Q3 24 | $43.5M | $-7.5M | ||
| Q2 24 | $8.1M | $-10.0M | ||
| Q1 24 | $8.3M | $-9.8M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | $-3.4M | ||
| Q1 25 | $4.7M | $-8.3M | ||
| Q4 24 | $66.5M | $-36.4M | ||
| Q3 24 | $43.4M | $-7.5M | ||
| Q2 24 | $8.1M | $-10.0M | ||
| Q1 24 | $8.1M | $-9.8M |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | -116.5% | ||
| Q1 25 | 19.8% | -1976.7% | ||
| Q4 24 | 287.5% | -2309.3% | ||
| Q3 24 | 166.0% | -225.7% | ||
| Q2 24 | 39.6% | -376.2% | ||
| Q1 24 | 32.3% | -573.0% |
| Q4 25 | 4.0% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 0.6% | 0.9% | ||
| Q1 25 | 1.2% | 35.6% | ||
| Q4 24 | 5.3% | 4.2% | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 0.6% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCBP
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
